Insomnia Drug Gains Fast-Track Status for Kids

Children and teens with insomnia may gain access to a new option, pending phase 3 trial results.

Updated on Nov. 4, 2026 in Sleep Disorders

Isometric editorial illustration of a single white capsule on a pale nightstand beside a closed-shade bedside lamp, evoking pediatric sleep treatment. — The FDA granted Breakthrough Therapy designation to daridorexant, an investigational insomnia drug, for children and teens aged 10 to under 18 pending phase 3 results. AI Illustration. Upload story photo >

The U.S. Food and Drug Administration granted Breakthrough Therapy designation to daridorexant, an investigational insomnia drug from Idorsia, for treating pediatric insomnia disorder. The designation is meant to speed development for children and adolescents aged 10 to under 18 who have trouble sleeping.

Why it matters

Pediatric insomnia has very few treatment options designed for younger patients, and the designation reflects a significant unmet medical need among children and adolescents. It signals that regulators see early evidence as promising enough to prioritize the drug's development, though it does not mean the drug is approved or available.

The finding comes from a phase 2 randomized, placebo-controlled dose-finding trial of 165 patients aged 10 to under 18 with insomnia disorder, some of whom had subthreshold autism or ADHD. Sleep was measured objectively with polysomnography, and daridorexant 50mg extended total sleep time by 50 minutes versus 20 minutes on placebo.

The players

Idorsia

Swiss pharmaceutical company developing daridorexant, an insomnia treatment.

U.S. Food and Drug Administration (FDA)

U.S. federal agency responsible for reviewing and approving drugs and granting expedited development designations.

The details

Daridorexant is a dual orexin receptor antagonist, a class of drug that blocks orexin, a brain chemical that promotes wakefulness, to help the brain settle into sleep. In the trial, participants were randomly assigned in equal groups to 10mg, 25mg, 50mg, or placebo taken once each evening. The primary measure was change in objective total sleep time on the first day, and the drug also improved sleep quality, morning alertness, and daytime functioning.

October 23, 2026: Idorsia presented pediatric and adult daridorexant results at Sleep Europe 2026.
November 4, 2026: FDA Breakthrough Therapy designation for pediatric insomnia was announced.

Health Landscape

Orexin receptor antagonists such as daridorexant represent a newer class of sleep medication that works differently from older sedatives. Pediatric insomnia has historically lacked drugs developed and tested specifically for children, so this designation marks a shift toward expanding evidence-based options for younger patients.

Parents of children with persistent sleep problems may want to ask their pediatrician about evaluation options, since this drug is not yet approved and remains investigational. Families should expect that phase 3 trials are still needed before any pediatric use becomes available.

The takeaway

Pediatric insomnia has long lacked medications studied specifically in children, and this designation signals regulators are prioritizing that gap. Parents concerned about a child's sleep should talk with a pediatrician about sleep habits and evaluation options.